Prostatic Neoplasms Clinical Trial
Official title:
A Phase II Study of Ixabepilone Prior to Surgery for High-risk Localized Prostate Cancer
The purpose of this research study is to determine the safety and effectiveness of the
investigational drug, Ixabepilone, in men with high risk prostate cancer who plan to receive
surgery.
Prostate cancer is a common and important health issue facing men in the United States. Most
patients with prostate cancer are identified when the disease is limited to the prostate
gland itself (localized prostate cancer). A standard treatment for some patients with
localized prostate cancer is removal of the prostate gland in an operation known as a
"radical prostatectomy." A sub-set of patients with localized prostate cancer can be
identified who are at high-risk of suffering a recurrence of prostate cancer after radical
prostatectomy. For these patients, additional treatments are being investigated to combine
with surgery in the hopes of increasing the chances for cure.
Several kinds of chemotherapy medicines have been used for advanced prostate cancer which
returns after initial therapy. Epothilones are a newly developed class of chemotherapy drugs
that appear promising for the treatment of many forms of cancer. Ixabepilone is drug in the
epothilone class of chemotherapy medicines that has shown encouraging results for the
treatment of advanced prostate cancer and other cancers in clinical trials.
This trial will include men with high-risk localized prostate cancer who will receive
treatment with ixabepilone (4 cycles over 12 weeks) prior to radical prostatectomy. The goal
of this trial will be to determine if analysis of genes and proteins in prostate cancer
tissue taken before and after treatment can be used to predict ixabepilone response. In
addition, this trial will evaluate the safety and feasibility of administering ixabepilone
prior to radical prostatectomy for patients at high-risk of developing recurrent prostate
cancer.
The study has three phases: Screening, Treatment and Follow-up
- Screening: Eligibility will be verified
- Treatment: Subjects will receive Ixabepilone, which will be administered every 21 days
for 4 cycles prior to surgery
- Follow up: Subjects will be followed every 6 months for up to 5 years.
In addition, tissue will be collected at the time of surgery for genetic and protein studies.
Blood will also be collected pre and post therapy for proteomic and/or genetic studies.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04964271 -
Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
|
||
| Completed |
NCT02546908 -
A Registry of Participants With Prostate Cancer in Asia
|
||
| Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
| Completed |
NCT01683994 -
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT04838613 -
Study of Diagnostic Performance of [18F]CTT1057 in BCR
|
Phase 3 | |
| Completed |
NCT02364531 -
A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
|
||
| Completed |
NCT01929655 -
Japanese BAY88-8223 Monotherapy Phase II Study
|
Phase 2 | |
| Active, not recruiting |
NCT05022849 -
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
|
Phase 1 | |
| Completed |
NCT03261999 -
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer
|
Phase 3 | |
| Terminated |
NCT04907227 -
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension
|
Phase 3 | |
| Active, not recruiting |
NCT03587285 -
A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT02217566 -
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
|
Phase 2 | |
| Not yet recruiting |
NCT04101305 -
Measurement of Circulating Tumor Cells in Prostate Cancer
|
||
| Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
| Terminated |
NCT03066154 -
Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer
|
Phase 1 | |
| Withdrawn |
NCT02905201 -
A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
N/A | |
| Completed |
NCT02692976 -
Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients
|
Phase 2 | |
| Terminated |
NCT01420965 -
Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
|
Phase 2 | |
| Completed |
NCT01441713 -
Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer
|
N/A |